- Career builder (2)
- Events (4)
- FDA (14)
- Interviews (6)
- Pharmacists (4)
- Technology (6)
Newsletter of the week
Submitted by lucky_pharmacist on Tue, 07/29/2008 - 17:19.
in
Dear Friends here is yet another newsletter giving you recent news & happenings in our field.
Statins May Protect Against Memory Loss
People at high risk for dementia who took cholesterol-lowering statins are half as likely to develop dementia as those who do not take statins, a new study shows. Details
Research indicates Tea may improve attention and focus
Drinking four to five cups of tea a day may help maintain a healthy mind and body, according to new research published in a supplement to the August issue of the Journal of Nutrition. Details
Biogenerics Would Reduce Health Care Costs for Patients, Says GPhA High Health Care Costs the Focus of Joint Economic Committee Hearing
The Generic Pharmaceutical Association (GPhA) today said the availability of a workable pathway that provides timely patient access to safe, affordable and life-saving biogeneric medicines would save consumers and the health care system billions of dollars. Details
Sanofi-aventis to acquire Symbion from Primary Health Care
French pharma company Sanofi-aventis has entered into a binding agreement with Primary Health Care Limited of Sydney, Australia to acquire Symbion CP Holdings in Australia. Details
Bayer's Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU
The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the anticoagulant rivaroxaban (Xarelto®), taken as one tablet, once-daily, for the prevention of venous blood clots in patients undergoing elective (planned) hip or knee replacement surgery. Details
Drug Makers Seek Antiobesity Blockbuster
A handful of drug companies are testing new ways to treat obesity after years of research into the condition have failed to produce a blockbuster for big pharma. Details
Merck puts HIV development program on hold
Canada's Ambrilia Biopharma says that Merck has placed the development program for the HIV therapy--MK-8122--on hold as it focuses on basic science efforts to evaluate other PL-100 prodrugs and formulation options. Ambrilia says that Merck is also exploring possible back-up compounds. Details
Do let me know about your view on this newsletter.
- lucky_pharmacist's blog
- Login or register to post comments
News letters
Dear lucky,
These kind of pharma research developments and drug information will definately update the market trends and product information as well.
Re: Newsletter
All should get information & should discuss the topics of their interest, this is what I want. You can also participate in discussions on PharmIndia forum. We also have good topics there for information sharing & discussion.
good news
Lucky
Very good, your focus is again on a clinically important issue. Thank You. Can you give us a brief on the side effects that may occur on prolonged use of statins?
Side effects of statins
In addition to the common side effects such as headaches, nausea and fever, other statin side effects can be much more serious.
An FDA approved statin called Baycol was recently pulled off the market due to serious side effects and even deaths. Two of the most troubling statin side effects include extreme muscle pain and muscle disease (statin induced myopathy), and serious liver problems.
Other potential statin side effects: Although muscle pain and statins and liver problems are of the most concern, much research has shown that statin side effects could include sexual dysfunction and performance problems, as well as memory loss, personality changes and irritability.
Statin medications decrease your body's supply of CoEnzyme Q10 (CoQ10), which is an essential nutrient for heart strength and function.
But still it finds lot of use & the report that it is good for brain made me to give its link in newsletter.
Based on info I collected from various sources I will shortly give a blog here or discussion post on PharmIndia.